|
SCAI Dx aims at defining a cell-identity biomarker for precise diagnosis of the skin immune cell cancers. This project defines a partnership between the University of Zürich and the Scailyte AG and implements a diagnostic trial integrating single-cell and artificial intelligence technologies.
|
